There are currently 298 active clinical trials seeking participants for Prostate Cancer research studies. The states with the highest number of trials for Prostate Cancer participants are California, New York, Texas and Ohio.
Pre-surgical Tirzepatide-assisted Weight Loss in Men With Diabetes and Prostate Cancer: A Pilot Feasibility Study
NCT06759701
Recruiting
The goal of this clinical research study is to determine how well a tirzepatide-assisted weight loss program works before a prostatectomy in patients with intermediate risk prostate cancer
Gender:
MALE
Ages:
18 years and above
Trial Updated:
08/20/2025
Locations: The University of Texas M. D. Anderson Cancer Center, Houston, Texas
Conditions: Diabetes, Prostate Cancer
Register for Updates
Copper Cu 64 PSMA I&T PET Imaging in Men With Newly Diagnosed Prostate Cancer
NCT06235151
Recruiting
This is a prospective, open-label Phase 3 study to evaluate copper Cu 64 PSMA I\&T injection for PET/CT imaging in patients with newly diagnosed unfavorable intermediate high-risk, high-risk or very high-risk prostate cancer.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
08/20/2025
Locations: Arkansas Urology, Little Rock, Arkansas +39 locations
Conditions: Prostate Cancer, Prostate Adenocarcinoma
Register for Updates
A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors
NCT06257264
Recruiting
This study is a first-in-human (FIH), Phase 1a/1b study of BG-68501, a cyclin-dependent kinase-2 inhibitor (CDK2i), to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of BG-68501 in participants with advanced, nonresectable, or metastatic solid tumors as monotherapy and in combination with fulvestrant with or without BGB-43395, a selective CDK4 inhibitor, in adults with hormone receptor positive (HR+)/human epidermal growth factor rece... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/19/2025
Locations: Hoag Memorial Presbyterian, Newport Beach, California +32 locations
Conditions: Breast Cancer, Small Cell Lung Cancer, Ovarian Cancer, Gastric Cancer, Hormone-receptor-positive Breast Cancer, Hormone Receptor Positive HER-2 Negative Breast Cancer, Advanced Solid Tumor, Endometrial Cancer, Prostate Cancer, TNBC - Triple-Negative Breast Cancer, GastroEsophageal Cancer, Bladder Cancer
Register for Updates
Study of Oral MRT-2359 in Selected Cancer Patients
NCT05546268
Recruiting
This Phase 1/2, open-label, multicenter study is conducted in patients with previously treated selected solid tumors, including non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), high-grade neuroendocrine cancer of any primary site, diffuse large B-cell lymphoma (DLBCL), and tumors with L-MYC or N-MYC amplification. Patients receive escalating doses of a GSPT1 molecular glue degrader MRT-2359 to determine safety, tolerability, maximum tolerated dose (MTD) and/or recommended Phase... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/19/2025
Locations: Honor Health Research Institute, Scottsdale, Arizona +21 locations
Conditions: NSCLC, SCLC, DLBCL, NSCLC With High or Low L-MYC or N-MYC Expression, High Grade Neuroendocrine Cancer, L-MYC and N-MYC Amplified Solid Tumors, HR-positive, HER2-negative Breast Cancer, Prostate Cancer
Register for Updates
Telmisartan in Prostate Cancer
NCT06168487
Recruiting
The goal of this clinical trial is to learn about the tolerability of telmisartan in patients with prostate cancer, but evidence for treatment efficacy will also be gathered.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
08/18/2025
Locations: Dartmouth Health, Lebanon, New Hampshire
Conditions: Prostate Cancer
Register for Updates
Adjuvant Curcumin to Assess Recurrence Free Survival in Patients Who Have Had a Radical Prostatectomy
NCT02064673
Recruiting
This is a prospective study to determine if the adjuvant use of Curcumin improves recurrence-free survival.
Gender:
MALE
Ages:
Between 30 years and 80 years
Trial Updated:
08/18/2025
Locations: UT Southwestern Medical Center, Dallas, Texas
Conditions: Prostate Cancer
Register for Updates
WALNUTS for POWER: Polyphenols, Omega-3 Fatty Acids, Weight Loss, and EneRgy
NCT03824652
Recruiting
This is a randomized control trial testing the effect of walnut supplementation on prostate cancer progression in 50 men with biopsy confirmed prostate cancer and planning to undergo RP. Patients consented to the study will be randomly assigned to either continue their usual diets (control arm) or to the walnut arm for 4-10 weeks depending on the window between their consent date and the date for RP.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
08/16/2025
Locations: Cedars-Sinai Medical Center, Los Angeles, California +1 locations
Conditions: Prostate Cancer
Register for Updates
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
NCT06465069
Recruiting
The purpose of this study is to find out whether the study drug, LY4052031, is safe, tolerable and effective in participants with advanced, or metastatic solid tumors including urothelial cancer. The study is conducted in two parts - phase Ia (dose-escalation, dose-optimization) and phase Ib (dose-expansion). The study will last up to approximately 4 years.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/15/2025
Locations: Sarah Cannon Research Institute at HealthOne, Denver, Colorado +23 locations
Conditions: Metastatic Solid Tumor, Recurrent Solid Tumor, Advanced Solid Tumor, Urinary Bladder Neoplasm, Triple Negative Breast Cancer, Non-small Cell Lung Cancer, Esophageal Cancer, Pancreatic Cancer, Ovarian Cancer, Cervical Cancer, Head and Neck Squamous Cell Carcinoma, Prostate Cancer, Renal Pelvis Cancer, Bladder Cancer
Register for Updates
A Study to Test Radium-223 With Docetaxel in Patients With Prostate Cancer
NCT03574571
Recruiting
The purpose of this study is to compare any good and bad effects of using radium-223 along with docetaxel chemotherapy treatment versus using docetaxel alone. Earlier studies helped show that the combination is safe, but the combination has not been proven to work better than either drug alone. The goal of this study is to find out if combining docetaxel and radium-223 is better than giving either drug by itself.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
08/15/2025
Locations: Banner MD Anderson Cancer Center, Gilbert, Arizona +71 locations
Conditions: Prostate Cancer
Register for Updates
Utility of 18F-rhPSMA-7.3 in the Diagnosis of Prostate Cancer After Focal Gland Treatment
NCT07011342
Recruiting
To evaluate the effectiveness of a PSMA-PET scan in identifying recurrent prostate cancer after focal therapy
Gender:
MALE
Ages:
18 years and above
Trial Updated:
08/15/2025
Locations: John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey
Conditions: Prostate Cancer
Register for Updates
T-reg Function Changes: a Novel Immune Regulatory Effect Underlying Benefit of Statin Use on Lethal Prostate Cancer
NCT05586360
Recruiting
This study will evaluate whether simvastatin reduces intraprostatic immunosuppressive microenvironment through YAP-mediated T-reg dysfunction, and increases intraprostatic anti-tumor immune response in men recently diagnosed with localized prostate cancer electing to receive prostatectomy for their care. Half the men will be randomized to receive statins for 8 weeks prior to their surgery, while the other half will receive standard of care.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
08/14/2025
Locations: Emory University, Atlanta, Georgia +1 locations
Conditions: Prostate Cancer
Register for Updates
Phase I/II Study of [225Ac]Ac-PSMA-R2 in PSMA-positive Prostate Cancer, With/Without Prior 177Lu-PSMA RLT
NCT05983198
Recruiting
This is an open label, phase I/II, multi-center study in adult participants with metastatic hormone sensitive prostate cancer (mHSPC) and with metastatic castration resistant prostate cancer (mCRPC) who have received prior anti-cancer treatment and have a positive 68Ga-PSMA-11 PET scan. The purpose of this study is to learn if the study drug, \[225Ac\]Ac-PSMA-R2, is safe and tolerable, and has anti-tumor activity in treated patients.
Gender:
MALE
Ages:
Between 18 years and 100 years
Trial Updated:
08/13/2025
Locations: Mayo Clinic Rochester, Rochester, Minnesota +10 locations
Conditions: Prostate Cancer
Register for Updates